Incruse Ellipta vs. Trelegy Ellipta

Incruse Ellipta (umeclidinium) Inhalation Powder and Trelegy Ellipta (fluticasone furoate, umeclidinium, and vilanterol inhalation powder) are used to treat patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema.

Both Incruse Ellipta and Trelegy Ellipta contain anticholinergic drugs. Trelegy Ellipta also contains a corticosteroid and a selective long-acting beta2-adrenergic agonist (LABA).

Side effects of Incruse Ellipta and Trelegy Ellipta that are similar include cough and sore throat.

Side effects of Incruse Ellipta that are different from Trelegy Ellipta include upper respiratory infection, stuffy or runny nose, joint pain, muscle pain, tooth pain, stomach pain, bruising or dark areas of skin, chest pain, fast or irregular heartbeat, and constipation.

Side effects of Trelegy Ellipta that are different from Incruse Ellipta include headache, back pain, changes in taste, diarrhea, mouth pain, and gastroenteritis (nausea, vomiting, cramps, and fever).

Both Incruse Ellipta and Trelegy Ellipta may interact with other anticholinergic drugs.

Trelegy Ellipta may also interact with ketoconazole and other azole antifungals, monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants, beta-blockers, diuretics, antiviral medications, conivaptan, nefazodone, and macrolide antibiotics.

Common side effects of Incruse Ellipta include:

• upper respiratory infection,
• stuffy or runny nose,
• cough,
• sore throat,
• joint pain,
• muscle pain,
• tooth pain,
• stomach pain,
• bruising or dark areas of skin,
• chest pain,
• fast or irregular heartbeat, and
• constipation.

Common side effects of Trelegy Ellipta include:

• headache,
• back pain,
• changes in taste,
• diarrhea,
• cough,
• mouth pain,
• sore throat,
• and gastroenteritis (nausea, vomiting, cramps, and fever).

Incruse Ellipta (umeclidinium) Inhalation Powder is an anticholinergic drug used for the long-term, once-daily, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema.

Trelegy Ellipta (fluticasone furoate, umeclidinium, and vilanterol inhalation powder), for oral inhalation is a combination of an inhaled corticosteroid (ICS), an anticholinergic, and a long-acting beta2-adrenergic agonist (LABA), indicated for the long-term once-daily, maintenance treatment of patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema, who are on a fixed-dose combination of fluticasone furoate and vilanterol for airflow obstruction and reducing exacerbations in whom additional treatment of airflow obstruction is desired or for patients who are already receiving umeclidinium and a fixed-dose combination of fluticasone furoate and vilanterol.

Incruse Ellipta may interact with other anticholinergic drugs. Tell your doctor all medications and supplements you use. During pregnancy, Incruse Ellipta should be taken only if prescribed. It is unknown if this drug passes into breast milk. Consult your doctor before breastfeeding.

Trelegy Ellipta may interact with ketoconazole and other azole antifungals, monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants, beta-blockers, diuretics, antocholinergics, antiviral medications, conivaptan, nefazodone, and macrolide antibiotics. Tell your doctor all medications and supplements you use. Tell your doctor if you are pregnant or plan to become pregnant before using Trelegy Ellipta; it is unknown how it would affect a fetus. It is unknown if Trelegy Ellipta passes into breast milk. Consult your doctor before breastfeeding.

Incruse Ellipta (umeclidinium 62.5 mcg) should be administered as 1 inhalation dose once daily by the orally inhaled route only. Incruse Ellipta may interact with other anticholinergic drugs. Tell your doctor all medications and supplements you use.

The dose of Trelegy Ellipta for maintenance treatment of COPD is 1 inhalation once daily.